Nonclinical Strategies for Refining Combination Rectal Formulations
$159,046U19FY2013AINIH
Magee-Women'S Res Inst And Foundation, Pittsburgh PA
Investigators
Linked publications, trials & patents
Paper 37563299Paper 34384282Paper 28296471Paper 27841671Paper 26227279Paper 25942472Paper 25647729Paper 25025306Paper 24952245Paper 24266648Paper 24188705Paper 23791525Paper 23612991Paper 23527295Paper 23115295Paper 23032732Paper 22940075Paper 22569301Paper 22264086Paper 22013053Paper 21799532Paper 21709824Paper 21593172Paper 21471432Paper 21331798Paper 20368766Trial NCT01575418Trial NCT01575405
Abstract
In the face of the existing HIV-1 epidemic, an effective mix of prevention modalities are needed to begin to reduce the incidence of HIV-1. This includes the used of topical microbicides. These are products that would be used to prevent the sexual transmission of HIV-1; including receptive anal intercourse. Project 1, Nonclinical Strategies for Refining Combination Rectal Formulations, of this U19 will strive to ensure that a safe and effective rectal microbicide will be developed. To date, the Phase 2b trials of
View original record on NIH RePORTER →